Key Figures Q2 2022

SEK m, unless otherwise stated

2022

Apr-Jun

2021

Apr-Jun

2022

Jan-Jun

2021

Jan-Jun

% Change

2021

Jan-Dec

Net revenues

147.8

142.8

307.3 275.1 3.5%

565.0

Cost of goods sold

-21.2

-18.1

-48.7 -37.4 17.5%

-78.9

Operating expenses

-176.4

-178.7

-321.5 -328.7 -1.3%

-700.2

EBIT

-49.7

-54.0

-62.9 -90.9 7.9%

-214.1

EBIT margin, %

-33.6%

-37.8%

-20.5% -33.1% 4.2%

-37.9%

EBITDA

-32.5

-41.1

-29.7 -65.2 20.9%

-161.0

Earnings per share, before dilution, SEK

-1.04

-2.15

-1.73 -3.07 51.6%

-6.51

Earnings per share, after dilution, SEK

-1.04

-2.15

-1.73 -3.07 51.6%

-6.51

Cash flow from operating activities

14.5

-20.9

-47.1 -68.7 169.5%

-229.0

Cash and cash equivalents

467.7

679.7

467.7 679.7 -31.2%

504.1

Net revenues and EBIT per segment Q2 2022

SEK m Net Revenues EBIT
  2022 Apr-Jun 2021 Apr-Jun 2022 Jan-Jun 2021 Jan-Jun 2021 Jan-Dec 2022 Apr-Jun 2021 Apr-Jun 2022 Jan-Jun 2021 Jan-Jun 2021 Jan-Dec
ZUBSOLV® US 139.6 126.0 278.7 252.8 522.7 - - - - -
US Pharma – total 139.6 126.0 278.7 252.8 522.7 77.2 61.6 161.2 127.7 278.2
Digital Therapeutics (DTx) product sales 0.1 0.3 0.3 0.4 1.1 - - - - -
Digital Therapeutics (DTx) – total 0.1 0.3 0.3 0.4 1.1 -47.9 -51.6 -91.3 -110.5 -249.7
Abstral® royalties 5.0 14.3 17.4 17.0 32.1 - - - - -
Edluar® royalties 1.6 2.3 4.8 4.9 9.1 - - - - -
ZUBSOLV® - ex US 1.5 - 6.1 - - - - - - -
HQ & Pipeline segment - total 8.1 16.5 28.3 21.9 41.2 -79.1 -63.9 -132.9 -108.2 -242.6
Total 147.8 142.8 307.3 275.1 565.0 -49.7 -54.0 -62.9 -90.9 -214.1

Cash flow Q2 2022

 

SEK m

2022

Apr-Jun

2021

Apr-Jun

2022

Jan-Jun

2021

Jan-Jun

2021

Jan-Dec

Cash flow from operating activities

14.5

-20.9

-47.1

-68.7

-299.0

Investment activities

-226.3

-13.1

-231.9

-29.3

-52.9

Financing activities

-5.3

-3.5

-10.6

258.2

250.6

Cash flow (excl exchange rate differences)

-217.0

-37.5

-289.6

160.1

-31,2

Liquid funds

244.2

679.7

244.2

679.7

504.1